A Prospective Cohort Study to Explore Biomarkers for Response to Neoadjuvant Chemoimmunotherapy in Stage II-III Non-small Cell Lung Cancer
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
1. To explore tissue-based biomarkers to select patients who do not respond to neoadjuvant immunotherapy (non-responders) at the point of diagnosis 2. To explore blood-based non-invasive biomarkers to predict pathological complete response (pCR) before surgery
Eligibility
Participation Requirements
Sex: All
Minimum Age: 19
Healthy Volunteers: f
View:
• Histologically proven clinical stage II-III lung cancer patients
• No driver mutations (EGFR mutation and ALK alteration)
• Whole body performance (ECOG) 0-1
• Those over 19 years of age
• Subject who submitted Informed consent form
Locations
Other Locations
Republic of Korea
Department of Thoracic and Cardiovascular Surgery, Severance Hospital, Yonsei University College of Medicine
RECRUITING
Seoul
Contact Information
Primary
Tae Hee Hong
thhongcs@yuhs.ac
(82)10-3487-6255
Time Frame
Start Date: 2024-08-07
Estimated Completion Date: 2029-06-30
Participants
Target number of participants: 100
Treatments
Neoadjuvant Immunotherapy
Establishment of a neoadjuvant ICI treatment cohort for resectable stage II-III lung cancer patients and acquisition of clinical-pathological-radiological data
Related Therapeutic Areas
Sponsors
Leads: Yonsei University